Wet AMD 5 Symposium

Related

• 

  Are There Safety Concerns With Bevacizumab for ROP

  Robert L. Avery, MD

  Updates from the Field

  2017

• 

  Anti-VEGF treatment switch in DME and nAMD: a comparison of aflibercept versus ranibizumab after a single-dose switch

  Estephania Feria, MD

  On Demand Cases, Courses, and Papers

  2019

• 

  Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study

  W. Lloyd Clark, MD, FASRS

  Updates from the Field

  2022